{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:21:22Z","timestamp":1789842082040,"version":"4.0.1"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-023-10338-x","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T02:03:48Z","timestamp":1691633028000},"page":"305-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials"],"prefix":"10.1007","volume":"29","author":[{"given":"Wu","family":"Meifang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Kaizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Meiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0259-5269","authenticated-orcid":false,"given":"Lin","family":"Liming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"10338_CR1","doi-asserted-by":"crossref","unstructured":"Becher PM, Lund LH, Coats AJS, Savarese G (2022) An update on global epidemiology in heart failure. Eur heart J","DOI":"10.1093\/eurheartj\/ehac248"},{"issue":"8","key":"10338_CR2","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","volume":"145","author":"CW Tsao","year":"2022","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y et al (2022) Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation 145(8):e153\u2013e639","journal-title":"Circulation"},{"issue":"21","key":"10338_CR3","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","volume":"64","author":"RJ Mentz","year":"2014","unstructured":"Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, Kjeldsen K, Jankowska EA, Atar D, Butler J et al (2014) Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 64(21):2281\u20132293","journal-title":"J Am Coll Cardiol"},{"key":"10338_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ijcard.2018.04.001","volume":"271","author":"KW Streng","year":"2018","unstructured":"Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Metra M, Ng LL et al (2018) Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol 271:132\u2013139","journal-title":"Int J Cardiol"},{"issue":"40","key":"10338_CR5","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske B, Tsch\u00f6pe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP et al (2019) How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 40(40):3297\u20133317","journal-title":"Eur Heart J"},{"issue":"6","key":"10338_CR6","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/ejhf.2169","volume":"23","author":"A Uijl","year":"2021","unstructured":"Uijl A, Savarese G, Vaartjes I, Dahlstr\u00f6m U, Brugts JJ, Linssen GCM, van Empel V, Brunner-La Rocca HP, Asselbergs FW, Lund LH et al (2021) Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. Eur J Heart Fail 23(6):973\u2013982","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10338_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101433","volume":"48","author":"A Palazzuoli","year":"2023","unstructured":"Palazzuoli A, Buono MGD, Ruocco G, Caravita S, Abbate A, Lavie CJ (2023) The conundrum of HFpEF definition: non-invasive assessment uncertainties and alternative diagnostic strategies. Curr Probl Cardiol 48(1):101433","journal-title":"Curr Probl Cardiol"},{"issue":"36","key":"10338_CR8","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726","journal-title":"Eur Heart J"},{"issue":"17","key":"10338_CR9","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B et al (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609\u20131620","journal-title":"N Engl J Med"},{"issue":"3","key":"10338_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/14656566.2022.2027909","volume":"23","author":"E Raschi","year":"2022","unstructured":"Raschi E, Diemberger I, Sabatino M, Poluzzi E, De Ponti F, Potena L (2022) Evaluating sacubitril\/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. Expert Opin Pharmacother 23(3):303\u2013320","journal-title":"Expert Opin Pharmacother"},{"issue":"16","key":"10338_CR11","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461","journal-title":"N Engl J Med"},{"issue":"17","key":"10338_CR12","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol 79(17):1757\u20131780","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10338_CR13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387(12):1089\u20131098","journal-title":"N Engl J Med"},{"issue":"6","key":"10338_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","volume":"145","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A et al (2022) Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation 145(6):437\u2013447","journal-title":"Circulation"},{"issue":"8","key":"10338_CR15","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41591-021-01452-0","volume":"27","author":"GA Lewis","year":"2021","unstructured":"Lewis GA, Dodd S, Clayton D, Bedson E, Eccleson H, Schelbert EB, Naish JH, Jimenez BD, Williams SG, Cunnington C et al (2021) Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat Med 27(8):1477\u20131482","journal-title":"Nat Med"},{"issue":"21","key":"10338_CR16","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","volume":"78","author":"P Palau","year":"2021","unstructured":"Palau P, Seller J, Dom\u00ednguez E, Sastre C, Ram\u00f3n JM, de La Espriella R, Santas E, Mi\u00f1ana G, Bod\u00ed V, Sanchis J et al (2021) Effect of \u03b2-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J Am Coll Cardiol 78(21):2042\u20132056","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10338_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/heartjnl-2021-319643","volume":"108","author":"A Singh","year":"2022","unstructured":"Singh A, Agarwal A, Wafford QE, Shah SJ, Huffman M, Khan S (2022) Efficacy and safety of diuretics in heart failure with preserved ejection fraction: a scoping review. Heart 108(8):593\u2013605","journal-title":"Heart"},{"key":"10338_CR18","doi-asserted-by":"crossref","unstructured":"Verbrugge FH, Menon V (2022) In perspective: torsemide comparison with furosemide for management of heart failure (TRANSFORM-HF) trial. Eur Heart J Acute Cardiovasc Care","DOI":"10.1093\/ehjacc\/zuac144"},{"issue":"6","key":"10338_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jacc.2020.06.022","volume":"76","author":"C Faselis","year":"2020","unstructured":"Faselis C, Arundel C, Patel S, Lam PH, Gottlieb SS, Zile MR, Deedwania P, Filippatos G, Sheriff HM, Zeng Q et al (2020) Loop diuretic prescription and 30-day outcomes in older patients with heart failure. J Am Coll Cardiol 76(6):669\u2013679","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10338_CR20","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/ejhf.757","volume":"19","author":"JM Ter Maaten","year":"2017","unstructured":"Ter Maaten JM, Rao VS, Hanberg JS, Perry Wilson F, Bellumkonda L, Assefa M, Sam Broughton J, D\u2019Ambrosi J, Wilson Tang WH, Damman K et al (2017) Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure. Eur J Heart Fail 19(8):1014\u20131022","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10338_CR21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/ejhf.811","volume":"19","author":"D Montero","year":"2017","unstructured":"Montero D, Flammer AJ (2017) Exercise intolerance in heart failure with preserved ejection fraction: time to scrutinize diuretic therapy? Eur J Heart Fail 19(8):971\u2013973","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10338_CR22","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/S0002-9149(00)00795-5","volume":"85","author":"DJ van Kraaij","year":"2000","unstructured":"van Kraaij DJ, Jansen RW, Bouwels LH, Gribnau FW, Hoefnagels WH (2000) Furosemide withdrawal in elderly heart failure patients with preserved left ventricular systolic function. Am J Cardiol 85(12):1461\u20131466","journal-title":"Am J Cardiol"},{"issue":"18","key":"10338_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009149","volume":"7","author":"MA Brisco-Bacik","year":"2018","unstructured":"Brisco-Bacik MA, Ter Maaten JM, Houser SR, Vedage NA, Rao V, Ahmad T, Wilson FP, Testani JM (2018) Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: a propensity analysis. J Am Heart Assoc 7(18):e009149","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10338_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008090","volume":"14","author":"SS Khan","year":"2021","unstructured":"Khan SS, Huffman MD, Shah SJ (2021) Could a low-dose diuretic polypill improve outcomes in heart failure with preserved ejection fraction? Circ Heart Fail 14(3):e008090","journal-title":"Circ Heart Fail"},{"key":"10338_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.752370","volume":"12","author":"S Pabel","year":"2021","unstructured":"Pabel S, Hamdani N, Singh J, Sossalla S (2021) Potential mechanisms of SGLT2 inhibitors for the treatment of heart failure With preserved ejection fraction. Front Physiol 12:752370","journal-title":"Front Physiol"},{"key":"10338_CR26","doi-asserted-by":"crossref","unstructured":"Wei J, Du J (2023)\u00a0Mechanisms of sodium-glucose cotransporter 2 inhibitors in heart failure. Cardiovasc Innov Appl\u00a08(1)","DOI":"10.15212\/CVIA.2023.0028"},{"issue":"16","key":"10338_CR27","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","volume":"144","author":"M Packer","year":"2021","unstructured":"Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M et al (2021) Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial. Circulation 144(16):1284\u20131294","journal-title":"Circulation"},{"issue":"12","key":"10338_CR28","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jacc.2022.01.029","volume":"79","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Butler J, Zannad F, Filippatos G, Schueler E, Steubl D, Zeller C, Januzzi JL, Pocock S, Packer M et al (2022) Mineralocorticoid receptor antagonists and empagliflozin in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 79(12):1129\u20131137","journal-title":"J Am Coll Cardiol"},{"key":"10338_CR29","doi-asserted-by":"crossref","unstructured":"Amerena JJH (2022) Outcomes of empagliflozin in patients with heart failure with a preserved ejection fraction and atrial fibrillation or atrial flutter: insights from EMPEROR-Preserved. Lung Circ 31:S93-S94","DOI":"10.1016\/j.hlc.2022.06.111"},{"key":"10338_CR30","doi-asserted-by":"crossref","unstructured":"Nicholls SJH (2022) Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of blood pressure\u2013the EMPEROR-Preserved trial.\u00a0Lung, Circ 31:S81-S82","DOI":"10.1016\/j.hlc.2022.06.085"},{"issue":"1","key":"10338_CR31","first-page":"1","volume":"80","author":"M B\u00f6hm","year":"2022","unstructured":"B\u00f6hm M, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Abdin A, Mahfoud F, Brueckmann M, Gollop ND, Iwata T et al (2022) Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age 80(1):1\u201318","journal-title":"Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age"},{"key":"10338_CR32","doi-asserted-by":"crossref","unstructured":"Yang M, Butt JH, Kondo T, Jering KS, Docherty KF, Jhund PS, de Boer RA, Claggett BL, Desai AS, Hernandez AF et al (2022)\u00a0Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril\/valsartan. Eur J Heart Fail","DOI":"10.1002\/ejhf.2722"},{"issue":"11","key":"10338_CR33","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, Khariton Y, Malik AO, Khumri T, Umpierrez G et al (2021) The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med 27(11):1954\u20131960","journal-title":"Nat Med"},{"issue":"4","key":"10338_CR34","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","volume":"28","author":"JA Spertus","year":"2022","unstructured":"Spertus JA, Birmingham MC, Nassif M, Damaraju CV, Abbate A, Butler J, Lanfear DE, Lingvay I, Kosiborod MN, Januzzi JL (2022) The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med 28(4):809\u2013813","journal-title":"Nat Med"},{"issue":"5","key":"10338_CR35","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2337\/dc21-2434","volume":"45","author":"P Mone","year":"2022","unstructured":"Mone P, Lombardi A, Gambardella J, Pansini A, Macina G, Morgante M, Frullone S, Santulli G (2022) Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. Diabetes Care 45(5):1247\u20131251","journal-title":"Diabetes Care"},{"issue":"2","key":"10338_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384(2):117\u2013128","journal-title":"N Engl J Med"},{"issue":"11","key":"10338_CR37","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993\u20131004","journal-title":"N Engl J Med"},{"issue":"9851","key":"10338_CR38","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","volume":"380","author":"SD Solomon","year":"2012","unstructured":"Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J et al (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (London, England) 380(9851):1387\u20131395","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10338_CR39","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","volume":"141","author":"SD Solomon","year":"2020","unstructured":"Solomon SD, Vaduganathan ML, Claggett B, Packer M, Zile M, Swedberg K, Rouleau J, A. Pfeffer M, Desai A, Lund L, Kober L et al (2020) Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. Circulation 141(5):352\u2013361","journal-title":"Circulation"},{"issue":"3","key":"10338_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","volume":"75","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Desai AS, Anker SD, Perrone SV, Janssens S, Milicic D, Arango JL, Packer M, Shi VC et al (2020) Prior heart failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF. J Am Coll Cardiol 75(3):245\u2013254","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10338_CR41","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jchf.2021.04.009","volume":"9","author":"M Gori","year":"2021","unstructured":"Gori M, Senni M, Claggett B, Liu J, Maggioni AP, Zile M, Prescott MF, Van Veldhuisen DJ, Zannad F, Pieske B et al (2021) Integrating high-sensitivity troponin T and sacubitril\/valsartan treatment in HFpEF: the PARAGON-HF trial. JACC Heart failure 9(9):627\u2013635","journal-title":"JACC Heart failure"},{"issue":"5","key":"10338_CR42","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jchf.2021.01.014","volume":"9","author":"M Vaduganathan","year":"2021","unstructured":"Vaduganathan M, Cunningham JW, Claggett BL, Causland FM, Barkoudah E, Finn P, Zannad F, Pfeffer MA, Rizkala AR, Sabarwal S et al (2021) Worsening heart failure episodes outside a hospital setting in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC Heart failure 9(5):374\u2013382","journal-title":"JACC Heart failure"},{"issue":"4","key":"10338_CR43","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1002\/ehf2.13952","volume":"9","author":"P Codina","year":"2022","unstructured":"Codina P, Domingo M, Barcel\u00f3 E, Gastelurrutia P, Casquete D, Vila J, Abdul-Jawad Altisent O, Spitaleri G, Cediel G, Santiago-Vacas E et al (2022) Sacubitril\/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension. ESC heart failure 9(4):2170\u20132180","journal-title":"ESC heart failure"},{"issue":"15","key":"10338_CR44","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383\u20131392","journal-title":"N Engl J Med"},{"issue":"1","key":"10338_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I et al (2015) Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131(1):34\u201342","journal-title":"Circulation"},{"issue":"5","key":"10338_CR46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","volume":"37","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O\u2019Meara E, Shah SJ, McKinlay S, Fleg JL et al (2016) Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37(5):455\u2013462","journal-title":"Eur Heart J"},{"key":"10338_CR47","doi-asserted-by":"crossref","unstructured":"Choy M, Liang W, He J, Fu M, Dong Y, He X, Liu C (2022)\u00a0Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment. ESC Heart Fail","DOI":"10.1002\/ehf2.13969"},{"key":"10338_CR48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.amjcard.2021.01.018","volume":"146","author":"K Elkholey","year":"2021","unstructured":"Elkholey K, Papadimitriou L, Butler J, Thadani U, Stavrakis S (2021) Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction. Am J Cardiol 146:36\u201347","journal-title":"Am J Cardiol"},{"issue":"13","key":"10338_CR49","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/bph.15747","volume":"179","author":"U Kintscher","year":"2022","unstructured":"Kintscher U, Bakris GL, Kolkhof P (2022) Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol 179(13):3220\u20133234","journal-title":"Br J Pharmacol"},{"issue":"15","key":"10338_CR50","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1080\/14656566.2022.2138744","volume":"23","author":"M Lorente-Ros","year":"2022","unstructured":"Lorente-Ros M, Aguilar-Gallardo JS, Shah A, Narasimhan B, Aronow WS (2022) An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook. Expert Opin Pharmacother 23(15):1737\u20131751","journal-title":"Expert Opin Pharmacother"},{"issue":"23","key":"10338_CR51","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219\u20132229","journal-title":"N Engl J Med"},{"issue":"24","key":"10338_CR52","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385(24):2252\u20132263","journal-title":"N Engl J Med"},{"key":"10338_CR53","doi-asserted-by":"crossref","unstructured":"Georgianos PI, Agarwal R (2022)\u00a0The non-steroidal MRA finerenone in cardiorenal medicine: a state-of-the-art review of the literature. Am J Hypertens","DOI":"10.1093\/ajh\/hpac124"},{"key":"10338_CR54","unstructured":"Bayer (2020) Study to evaluate the efficacy (effect on disease) and safety of finerenone on morbidity (events indicating disease worsening) and mortality (death rate) in participants with heart failure and left ventricular ejection fraction (proportion of blood expelled per heart stroke) greater or equal to 40%(FINEARTS-HF)"},{"issue":"9386","key":"10338_CR55","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J (2003) Effects of Candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet (London, England) 362(9386):777\u2013781","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10338_CR56","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.1149","volume":"20","author":"LH Lund","year":"2018","unstructured":"Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA et al (2018) Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 20(8):1230\u20131239","journal-title":"Eur J Heart Fail"},{"key":"10338_CR57","doi-asserted-by":"crossref","unstructured":"Martin N, Manoharan K, Davies C, Lumbers RT (2021)\u00a0Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev 5(5):Cd012721","DOI":"10.1002\/14651858.CD012721.pub3"},{"issue":"8","key":"10338_CR58","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006213","volume":"12","author":"M Meyer","year":"2019","unstructured":"Meyer M, LeWinter MM (2019) Heart rate and heart failure with preserved ejection fraction: time to slow \u03b2-blocker use? Circ Heart Fail 12(8):e006213","journal-title":"Circ Heart Fail"},{"issue":"8","key":"10338_CR59","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.004969","volume":"11","author":"A Zweerink","year":"2018","unstructured":"Zweerink A, van der Lingen ACJ, Handoko ML, van Rossum AC, Allaart CP (2018) Chronotropic incompetence in chronic heart failure. Circ Heart Fail 11(8):e004969","journal-title":"Circ Heart Fail"},{"issue":"12","key":"10338_CR60","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.16598","volume":"2","author":"DN Silverman","year":"2019","unstructured":"Silverman DN, Plante TB, Infeld M, Callas PW, Juraschek SP, Dougherty GB, Meyer M (2019) Association of \u03b2-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial. JAMA Netw Open 2(12):e1916598","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10338_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.025","volume":"79","author":"L Fauchier","year":"2022","unstructured":"Fauchier L, Bodin A, Bisson A (2022) Beta-blocker withdrawal and chronotropic incompetence in heart failure with preserved ejection fraction. J Am Coll Cardiol 79(9):e195","journal-title":"J Am Coll Cardiol"},{"key":"10338_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104694","volume":"155","author":"A Aimo","year":"2020","unstructured":"Aimo A, Cerbai E, Bartolucci G, Adamo L, Barison A, Lo Surdo G, Biagini S, Passino C, Emdin M (2020) Pirfenidone is a cardioprotective drug: mechanisms of action and preclinical evidence. Pharmacol Res 155:104694","journal-title":"Pharmacol Res"},{"issue":"20","key":"10338_CR63","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.jacc.2016.08.048","volume":"68","author":"D Kotecha","year":"2016","unstructured":"Kotecha D, Lam CS, Van Veldhuisen DJ, Van Gelder IC, Voors AA, Rienstra M (2016) Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J Am Coll Cardiol 68(20):2217\u20132228","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10338_CR64","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jchf.2022.01.018","volume":"10","author":"M Cikes","year":"2022","unstructured":"Cikes M, Planinc I, Claggett B, Cunningham J, Milicic D, Sweitzer N, Senni M, Gori M, Linssen G, Shah SJ et al (2022) Atrial fibrillation in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC Heart failure 10(5):336\u2013346","journal-title":"JACC Heart failure"},{"issue":"5","key":"10338_CR65","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE et al (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42(5):373\u2013498","journal-title":"Eur Heart J"},{"issue":"21","key":"10338_CR66","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1161\/CIRCULATIONAHA.122.060243","volume":"146","author":"EN Prystowsky","year":"2022","unstructured":"Prystowsky EN (2022) Rate versus rhythm control for atrial fibrillation: has the debate been settled? Circulation 146(21):1561\u20131563","journal-title":"Circulation"},{"issue":"24","key":"10338_CR67","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011560","volume":"8","author":"JP Kelly","year":"2019","unstructured":"Kelly JP, DeVore AD, Wu J, Hammill BG, Sharma A, Cooper LB, Felker GM, Piccini JP, Allen LA, Heidenreich PA et al (2019) Rhythm control versus rate control in patients with atrial fibrillation and heart failure with preserved ejection fraction: insights from get with the guidelines-heart failure. J Am Heart Assoc 8(24):e011560","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10338_CR68","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jjcc.2019.02.014","volume":"74","author":"T Machino-Ohtsuka","year":"2019","unstructured":"Machino-Ohtsuka T, Seo Y, Ishizu T, Yamamoto M, Hamada-Harimura Y, Machino T, Yamasaki H, Sekiguchi Y, Nogami A, Aonuma K et al (2019) Relationships between maintenance of sinus rhythm and clinical outcomes in patients with heart failure with preserved ejection fraction and atrial fibrillation. J Cardiol 74(3):235\u2013244","journal-title":"J Cardiol"},{"issue":"11","key":"10338_CR69","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.121.056323","volume":"144","author":"A Rillig","year":"2021","unstructured":"Rillig A, Magnussen C, Ozga AK, Suling A, Brandes A, Breithardt G, Camm AJ, Crijns H, Eckardt L, Elvan A et al (2021) Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation 144(11):845\u2013858","journal-title":"Circulation"},{"issue":"11","key":"10338_CR70","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1161\/CIRCULATIONAHA.122.060274","volume":"146","author":"A Rillig","year":"2022","unstructured":"Rillig A, Borof K, Breithardt G, Camm AJ, Crijns H, Goette A, Kuck KH, Metzner A, Vardas P, Vettorazzi E et al (2022) Early rhythm control in patients with atrial fibrillation and high comorbidity burden. Circulation 146(11):836\u2013847","journal-title":"Circulation"},{"issue":"14","key":"10338_CR71","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.120.050991","volume":"143","author":"DL Packer","year":"2021","unstructured":"Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, Poole JE, Bahnson TD, Lee KL, Mark DB (2021) Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation 143(14):1377\u20131390","journal-title":"Circulation"},{"issue":"5","key":"10338_CR72","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/ejhf.2122","volume":"23","author":"H Sugumar","year":"2021","unstructured":"Sugumar H, Nanayakkara S, Vizi D, Wright L, Chieng D, Leet A, Mariani JA, Voskoboinik A, Prabhu S, Taylor AJ et al (2021) A prospective study using invasive haemodynamic measurements following catheter ablation for AF and early HFpEF: STALL AF-HFpEF. Eur J Heart Fail 23(5):785\u2013796","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"10338_CR73","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1001\/jama.2020.23138","volume":"324","author":"D Kotecha","year":"2020","unstructured":"Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, Haynes S, Calvert MJ, Deeks JJ, Steeds RP et al (2020) Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA 324(24):2497\u20132508","journal-title":"JAMA"},{"issue":"22","key":"10338_CR74","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373(22):2103\u20132116","journal-title":"N Engl J Med"},{"issue":"14","key":"10338_CR75","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, Yang J, Jiang Y, Xu X, Wang TD et al (2021) Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med 385(14):1268\u20131279","journal-title":"N Engl J Med"},{"issue":"17","key":"10338_CR76","first-page":"e426","volume":"138","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW et al (2018) 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation 138(17):e426\u2013e483","journal-title":"Circulation"},{"issue":"8","key":"10338_CR77","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1097\/HJH.0000000000002910","volume":"39","author":"A Kasiakogias","year":"2021","unstructured":"Kasiakogias A, Rosei EA, Camafort M, Ehret G, Faconti L, Ferreira JP, Brguljan J, Januszewicz A, Kahan T, Manolis A et al (2021) Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. J Hypertens 39(8):1522\u20131545","journal-title":"J Hypertens"},{"issue":"19","key":"10338_CR78","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JG Cleland","year":"2006","unstructured":"Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27(19):2338\u20132345","journal-title":"Eur Heart J"},{"issue":"3","key":"10338_CR79","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ejhf.2403","volume":"24","author":"AM Jackson","year":"2022","unstructured":"Jackson AM, R\u00f8rth R, Liu J, Kristensen SL, Anand IS, Claggett BL, Cleland JGF, Chopra VK, Desai AS, Ge J et al (2022) Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 24(3):497\u2013509","journal-title":"Eur J Heart Fail"},{"key":"10338_CR80","doi-asserted-by":"publisher","first-page":"3366109","DOI":"10.1155\/2022\/3366109","volume":"2022","author":"J Benko","year":"2022","unstructured":"Benko J, Samo\u0161 M, Bolek T, Pr\u00eddavkov\u00e1 D, Jurica J, P\u00e9\u010d MJ, Galajda P, Mok\u00e1\u0148 M (2022) Diabetic heart failure with preserved left ventricular ejection fraction: review of current pharmacotherapy. J Diabetes Res 2022:3366109","journal-title":"J Diabetes Res"},{"key":"10338_CR81","doi-asserted-by":"crossref","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G et al (2022)\u00a0Management of hyperglycemia in type 2 diabetes, 2022. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care","DOI":"10.2337\/figshare.20800537.v1"},{"issue":"11","key":"10338_CR82","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.mayocp.2018.07.018","volume":"93","author":"S Carbone","year":"2018","unstructured":"Carbone S, Dixon DL, Buckley LF, Abbate A (2018) Glucose-lowering therapies for cardiovascular risk reduction in type 2 diabetes mellitus: state-of-the-art review. Mayo Clin Proc 93(11):1629\u20131647","journal-title":"Mayo Clin Proc"},{"key":"10338_CR83","doi-asserted-by":"publisher","first-page":"8838026","DOI":"10.1155\/2021\/8838026","volume":"2021","author":"K Yagi","year":"2021","unstructured":"Yagi K, Imamura T, Tada H, Chujo D, Liu J, Shima Y, Ohbatake A, Miyamoto Y, Okazaki S, Ito N et al (2021) Diastolic cardiac function improvement by liraglutide is mainly body weight reduction dependent but independently contributes to B-type natriuretic peptide reduction in patients with type 2 diabetes with preserved ejection fraction. J Diabetes Res 2021:8838026","journal-title":"J Diabetes Res"},{"issue":"5","key":"10338_CR84","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM et al (2016) Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316(5):500\u2013508","journal-title":"JAMA"},{"issue":"1","key":"10338_CR85","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, H\u00e4nselmann A, Nilsson B, M\u00f8ller JE, Hjort J, Rasmussen J et al (2017) Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19(1):69\u201377","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10338_CR86","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-020-01100-w","volume":"19","author":"A Halabi","year":"2020","unstructured":"Halabi A, Sen J, Huynh Q, Marwick TH (2020) Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. Cardiovasc Diabetol 19(1):124","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"10338_CR87","volume":"13","author":"O Mgbemena","year":"2021","unstructured":"Mgbemena O, Zhang Y, Velarde G (2021) Role of diabetes mellitus in heart failure with preserved ejection fraction: a review article. Cureus 13(11):e19398","journal-title":"Cureus"},{"issue":"1","key":"10338_CR88","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA (2017) Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 136(1):6\u201319","journal-title":"Circulation"},{"issue":"21","key":"10338_CR89","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, Despr\u00e9s JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P et al (2021) Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 143(21):e984\u2013e1010","journal-title":"Circulation"},{"issue":"1","key":"10338_CR90","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jama.2015.17346","volume":"315","author":"DW Kitzman","year":"2016","unstructured":"Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, Eggebeen J, Nicklas BJ (2016) Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 315(1):36\u201346","journal-title":"JAMA"},{"key":"10338_CR91","doi-asserted-by":"crossref","unstructured":"Brubaker PH, Nicklas BJ, Houston DK, Hundley WG, Chen H, Molina M, Lyles WM, Nelson B, Upadhya B, Newland R et al (2022)\u00a0A randomized, controlled trial of resistance training added to caloric restriction plus aerobic exercise training in obese heart failure with preserved ejection fraction. Circ Heart Fail","DOI":"10.1161\/CIRCHEARTFAILURE.122.010161"},{"issue":"4","key":"10338_CR92","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10741-019-09774-5","volume":"24","author":"H Fukuta","year":"2019","unstructured":"Fukuta H, Goto T, Wakami K, Kamiya T, Ohte N (2019) Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Heart Fail Rev 24(4):535\u2013547","journal-title":"Heart Fail Rev"},{"key":"10338_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.983961","volume":"13","author":"FF Kreiner","year":"2022","unstructured":"Kreiner FF, Hovingh GKK, von Scholten BJ (2022) The potential of glucagon-like peptide-1 receptor agonists in heart failure. Front Physiol 13:983961","journal-title":"Front Physiol"},{"issue":"2","key":"10338_CR94","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 327(2):138\u2013150","journal-title":"JAMA"},{"key":"10338_CR95","doi-asserted-by":"crossref","unstructured":"le Roux C, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM (2023)\u00a051-OR: a phase 2, randomized, double-blind, placebo-controlled, dose-finding study of BI 456906 in people with overweight\/obesity. Diabetes\u00a072(Supplement_1)","DOI":"10.2337\/db23-51-OR"},{"key":"10338_CR96","unstructured":"Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC et al (2023)\u00a0Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England)"},{"key":"10338_CR97","doi-asserted-by":"crossref","unstructured":"Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z et al (2023)\u00a0Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London, England)","DOI":"10.1016\/S0140-6736(23)01053-X"},{"key":"10338_CR98","doi-asserted-by":"crossref","unstructured":"Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, Rubino DM, Garvey WT (2023)\u00a0Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England)","DOI":"10.1016\/S0140-6736(23)01185-6"},{"key":"10338_CR99","doi-asserted-by":"crossref","unstructured":"Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, Kazda C, Mather KJ, Haupt A, Pratt E et al (2023)\u00a0Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet (London, England)","DOI":"10.1016\/S0140-6736(23)01302-8"},{"issue":"8","key":"10338_CR100","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jchf.2018.01.009","volume":"6","author":"M Packer","year":"2018","unstructured":"Packer M, Kitzman DW (2018) Obesity-related heart failure with a preserved ejection fraction: the mechanistic rationale for combining inhibitors of aldosterone, neprilysin, and sodium-glucose cotransporter-2. JACC Heart failure 6(8):633\u2013639","journal-title":"JACC Heart failure"},{"issue":"8","key":"10338_CR101","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11906-020-01074-w","volume":"22","author":"K Ayinapudi","year":"2020","unstructured":"Ayinapudi K, Samson R, Le Jemtel TH, Marrouche NF, Oparil S (2020) Weight reduction for obesity-induced heart failure with preserved ejection fraction. Curr Hypertens Rep 22(8):47","journal-title":"Curr Hypertens Rep"},{"issue":"2","key":"10338_CR102","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/oby.22038","volume":"26","author":"D Mikhalkova","year":"2018","unstructured":"Mikhalkova D, Holman SR, Jiang H, Saghir M, Novak E, Coggan AR, O\u2019Connor R, Bashir A, Jamal A, Ory DS et al (2018) Bariatric surgery-induced cardiac and lipidomic changes in obesity-related heart failure with preserved ejection fraction. Obesity (Silver Spring, Md) 26(2):284\u2013290","journal-title":"Obesity (Silver Spring, Md)"},{"key":"10338_CR103","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3389\/fphys.2019.01108","volume":"10","author":"J van de Wouw","year":"2019","unstructured":"van de Wouw J, Broekhuizen M, Sorop O, Joles JA, Verhaar MC, Duncker DJ, Danser AHJ, Merkus D (2019) Chronic kidney disease as a risk factor for heart failure with preserved ejection fraction: a focus on microcirculatory factors and therapeutic targets. Front Physiol 10:1108","journal-title":"Front Physiol"},{"issue":"4","key":"10338_CR104","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ejhf.2471","volume":"24","author":"W Mullens","year":"2022","unstructured":"Mullens W, Martens P, Testani JM, Tang WHW, Skouri H, Verbrugge FH, Fudim M, Iacoviello M, Franke J, Flammer AJ et al (2022) Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 24(4):603\u2013619","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10338_CR105","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/2047487318780035","volume":"25","author":"T Tsujimoto","year":"2018","unstructured":"Tsujimoto T, Kajio H (2018) Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease. Eur J Prev Cardiol 25(12):1268\u20131277","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"10338_CR106","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/ejhf.232","volume":"17","author":"AA Voors","year":"2015","unstructured":"Voors AA, Gori M, Liu LC, Claggett B, Zile MR, Pieske B, McMurray JJ, Packer M, Shi V, Lefkowitz MP et al (2015) Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 17(5):510\u2013517","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"10338_CR107","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","volume":"142","author":"FR Mc Causland","year":"2020","unstructured":"Mc Causland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M, Jhund PS, McGrath MM, Packer M, Shi V et al (2020) Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation 142(13):1236\u20131245","journal-title":"Circulation"},{"issue":"5","key":"10338_CR108","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ejhf.2450","volume":"24","author":"A Peikert","year":"2022","unstructured":"Peikert A, Vaduganathan M, Mc Causland F, Claggett BL, Chatur S, Packer M, Pfeffer MA, Zannad F, Lefkowitz MP, Pieske B et al (2022) Effects of sacubitril\/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF. Eur J Heart Fail 24(5):794\u2013803","journal-title":"Eur J Heart Fail"},{"key":"10338_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175053","volume":"928","author":"R Jia","year":"2022","unstructured":"Jia R, Zhang X, Xu Y, Zheng Z, Jiang L, Zhang X, Sun C, Wu X, Li S, Raj A et al (2022) Effect of sacubitril\/valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: a real-world 12-week study. Eur J Pharmacol 928:175053","journal-title":"Eur J Pharmacol"},{"issue":"15","key":"10338_CR110","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"issue":"10","key":"10338_CR111","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/ejhf.2334","volume":"23","author":"M Packer","year":"2021","unstructured":"Packer M, Zannad F, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Brueckmann M, Zeller C, Hauske S, Anker SD (2021) Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. Eur J Heart Fail 23(10):1798\u20131799","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"10338_CR112","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1056\/NEJMc2112411","volume":"385","author":"M Packer","year":"2021","unstructured":"Packer M, Butler J, Zannad F, Pocock SJ, Filippatos G, Ferreira JP, Brueckmann M, Jamal W, Zeller C, Wanner C et al (2021) Empagliflozin and major renal outcomes in heart Failure. N Engl J Med 385(16):1531\u20131533","journal-title":"N Engl J Med"},{"key":"10338_CR113","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.15420\/ecr.2021.33","volume":"17","author":"DK Ryan","year":"2022","unstructured":"Ryan DK, Banerjee D, Jouhra F (2022) Management of heart failure in patients with chronic kidney disease. Eur Cardiol 17","journal-title":"Eur Cardiol"},{"issue":"10","key":"10338_CR114","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/ckj\/sfac133","volume":"15","author":"AB M\u00e9ndez","year":"2022","unstructured":"M\u00e9ndez AB, Azancot MA, Olivella A, Soler MJ (2022) New aspects in cardiorenal syndrome and HFpEF. Clin Kidney J 15(10):1807\u20131815","journal-title":"Clin Kidney J"},{"issue":"13","key":"10338_CR115","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","volume":"53","author":"CS Lam","year":"2009","unstructured":"Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM (2009) Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53(13):1119\u20131126","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10338_CR116","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/j.chest.2021.08.039","volume":"160","author":"C Inampudi","year":"2021","unstructured":"Inampudi C, Silverman D, Simon MA, Leary PJ, Sharma K, Houston BA, Vachi\u00e9ry JL, Haddad F, Tedford RJ (2021) Pulmonary hypertension in the context of heart failure with preserved ejection fraction. Chest 160(6):2232\u20132246","journal-title":"Chest"},{"key":"10338_CR117","doi-asserted-by":"crossref","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P et al\u00a0(2022) ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J","DOI":"10.1183\/13993003.00879-2022"},{"key":"10338_CR118","doi-asserted-by":"crossref","unstructured":"Vachi\u00e9ry JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, Coghlan G, Chazova I, De Marco T (2019)\u00a0Pulmonary hypertension due to left heart\u00a0disease. Eur Respir J\u00a053(1)","DOI":"10.1183\/13993003.01897-2018"},{"issue":"5","key":"10338_CR119","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.hlc.2016.09.004","volume":"26","author":"B Koller","year":"2017","unstructured":"Koller B, Steringer-Mascherbauer R, Ebner CH, Weber T, Ammer M, Eichinger J, Pretsch I, Herold M, Schwaiger J, Ulmer H et al (2017) Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-trial). Heart Lung Circ 26(5):433\u2013441","journal-title":"Heart Lung Circ"},{"issue":"38","key":"10338_CR120","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","volume":"36","author":"ES Hoendermis","year":"2015","unstructured":"Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, van Veldhuisen DJ, Voors AA (2015) Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 36(38):2565\u20132573","journal-title":"Eur Heart J"},{"issue":"2","key":"10338_CR121","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","volume":"124","author":"M Guazzi","year":"2011","unstructured":"Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124(2):164\u2013174","journal-title":"Circulation"},{"key":"10338_CR122","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijcard.2018.12.078","volume":"283","author":"T Kramer","year":"2019","unstructured":"Kramer T, Dumitrescu D, Gerhardt F, Orlova K, Ten Freyhaus H, Hellmich M, Baldus S, Rosenkranz S (2019) Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. Int J Cardiol 283:152\u2013158","journal-title":"Int J Cardiol"},{"issue":"4","key":"10338_CR123","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jacc.2016.05.047","volume":"68","author":"CF Opitz","year":"2016","unstructured":"Opitz CF, Hoeper MM, Gibbs JS, Kaemmerer H, Pepke-Zaba J, Coghlan JG, Scelsi L, D\u2019Alto M, Olsson KM, Ulrich S et al (2016) Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 68(4):368\u2013378","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10338_CR124","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1161\/CIRCRESAHA.118.313832","volume":"124","author":"YNV Reddy","year":"2019","unstructured":"Reddy YNV, Obokata M, Koepp KE, Egbe AC, Wiley B, Borlaug BA (2019) The \u03b2-adrenergic agonist albuterol improves pulmonary vascular reserve in heart failure with preserved ejection fraction. Circ Res 124(2):306\u2013314","journal-title":"Circ Res"},{"issue":"5","key":"10338_CR125","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jchf.2021.01.015","volume":"9","author":"D Burkhoff","year":"2021","unstructured":"Burkhoff D, Borlaug BA, Shah SJ, Zolty R, Tedford RJ, Thenappan T, Zamanian RT, Mazurek JA, Rich JD, Simon MA et al (2021) Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized placebo-controlled HELP trial. JACC Heart failure 9(5):360\u2013370","journal-title":"JACC Heart failure"},{"issue":"3","key":"10338_CR126","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jcin.2018.09.021","volume":"12","author":"H Zhang","year":"2019","unstructured":"Zhang H, Zhang J, Chen M, Xie DJ, Kan J, Yu W, Li XB, Xu T, Gu Y, Dong J et al (2019) Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre- and post-capillary pulmonary hypertension associated with left heart failure: the PADN-5 study. JACC Cardiovasc Interv 12(3):274\u2013284","journal-title":"JACC Cardiovasc Interv"},{"key":"10338_CR127","unstructured":"(2021) A study of sotatercept for the treatment of Cpc-PH due to HFpEF (MK-7962-007\/A011-16) (CADENCE) - full text view - ClinicalTrials.gov [Internet]. [cited 2023 Jul 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04945460"},{"issue":"16","key":"10338_CR128","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Gr\u00fcnig E et al (2023) Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med 388(16):1478\u20131490","journal-title":"N Engl J Med"},{"issue":"6","key":"10338_CR129","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/eurjhf\/hfp057","volume":"11","author":"T Bitter","year":"2009","unstructured":"Bitter T, Faber L, Hering D, Langer C, Horstkotte D, Oldenburg O (2009) Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail 11(6):602\u2013608","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10338_CR130","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.cardfail.2011.01.013","volume":"17","author":"TE Herrscher","year":"2011","unstructured":"Herrscher TE, Akre H, \u00d8verland B, Sandvik L, Westheim AS (2011) High prevalence of sleep apnea in heart failure outpatients: even in patients with preserved systolic function. J Card Fail 17(5):420\u2013425","journal-title":"J Card Fail"},{"issue":"3","key":"10338_CR131","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1136\/heartjnl-2020-317326","volume":"107","author":"JE Sanderson","year":"2021","unstructured":"Sanderson JE, Fang F, Lu M, Ma CY, Wei YX (2021) Obstructive sleep apnoea, intermittent hypoxia and heart failure with a preserved ejection fraction. Heart 107(3):190\u2013194","journal-title":"Heart"},{"issue":"4","key":"10338_CR132","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.amjcard.2018.04.052","volume":"122","author":"A Abdullah","year":"2018","unstructured":"Abdullah A, Eigbire G, Salama A, Wahab A, Nadkarni N, Alweis R (2018) Relation of obstructive sleep apnea to risk of hospitalization in patients with heart failure and preserved ejection fraction from the national inpatient sample. Am J Cardiol 122(4):612\u2013615","journal-title":"Am J Cardiol"},{"issue":"2","key":"10338_CR133","first-page":"335","volume":"15","author":"SP Patil","year":"2019","unstructured":"Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG (2019) Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med\u202f: JCSM\u202f: Offic Publication Am Acad Sleep Med 15(2):335\u2013343","journal-title":"J Clin Sleep Med : JCSM : Offic Publication Am Acad Sleep Med"},{"key":"10338_CR134","doi-asserted-by":"crossref","unstructured":"Randerath W, Verbraecken J, de Raaff CAL, Hedner J, Herkenrath S, Hohenhorst W, Jakob T, Marrone O, Marklund M, McNicholas WT et al (2021)\u00a0European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea. Eur Res Rev : Offic J Eur Respir Soc 30(162)","DOI":"10.1183\/16000617.0200-2021"},{"issue":"3","key":"10338_CR135","doi-asserted-by":"publisher","first-page":"151","DOI":"10.14503\/THIJ-15-5678","volume":"45","author":"HK Khattak","year":"2018","unstructured":"Khattak HK, Hayat F, Pamboukian SV, Hahn HS, Schwartz BP, Stein PK (2018) Obstructive sleep apnea in heart failure: review of prevalence, treatment with continuous positive airway pressure, and prognosis. Tex Heart Inst J 45(3):151\u2013161","journal-title":"Tex Heart Inst J"},{"issue":"5","key":"10338_CR136","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurjhf\/hfs197","volume":"15","author":"A Yoshihisa","year":"2013","unstructured":"Yoshihisa A, Suzuki S, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Suzuki H, Saitoh S, Takeishi Y (2013) Impact of adaptive servo-ventilation on cardiovascular function and prognosis in heart failure patients with preserved left ventricular ejection fraction and sleep-disordered breathing. Eur J Heart Fail 15(5):543\u2013550","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10338_CR137","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.jacc.2017.01.041","volume":"69","author":"CM O'Connor","year":"2017","unstructured":"O\u2019Connor CM, Whellan DJ, Fiuzat M, Punjabi NM, Tasissa G, Anstrom KJ, Benjafield AV, Woehrle H, Blase AB, Lindenfeld J et al (2017) Cardiovascular outcomes with minute ventilation-targeted adaptive servo-ventilation therapy in heart failure: the CAT-HF trial. J Am Coll Cardiol 69(12):1577\u20131587","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10338_CR138","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMoa1606599","volume":"375","author":"RD McEvoy","year":"2016","unstructured":"McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R, Drager LF, Liu Z et al (2016) CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 375(10):919\u2013931","journal-title":"N Engl J Med"},{"issue":"10","key":"10338_CR139","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMe1609704","volume":"375","author":"B Mokhlesi","year":"2016","unstructured":"Mokhlesi B, Ayas NT (2016) Cardiovascular events in obstructive sleep apnea - can CPAP therapy save lives? N Engl J Med 375(10):994\u2013996","journal-title":"N Engl J Med"},{"key":"10338_CR140","doi-asserted-by":"crossref","unstructured":"Kittleson MM, Panjrath GS, Amancherla K, Davis LL, Deswal A, Dixon DL, Januzzi JL, Yancy CW (2023) ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction. 0(0)","DOI":"10.1016\/j.jacc.2023.03.393"},{"issue":"1","key":"10338_CR141","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/eurheartj\/ehac569","volume":"44","author":"G Savarese","year":"2023","unstructured":"Savarese G, von Haehling S, Butler J, Cleland JGF, Ponikowski P, Anker SD (2023) Iron deficiency and cardiovascular disease. Eur Heart J 44(1):14\u201327","journal-title":"Eur Heart J"},{"issue":"7","key":"10338_CR142","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s11886-023-01889-4","volume":"25","author":"A Shamsi","year":"2023","unstructured":"Shamsi A, Cannata A, Piper S, Bromage DI, McDonagh TA (2023) Treatment of iron deficiency in heart failure. Curr Cardiol Rep 25(7):649\u2013661","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"10338_CR143","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/ehf2.13204","volume":"8","author":"A Barandiar\u00e1n Aizpurua","year":"2021","unstructured":"Barandiar\u00e1n Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca HP, Henkens M, Weerts J, Spanjers MHA, Knackstedt C, van Empel VPM (2021) Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction. ESC heart failure 8(2):1304\u20131313","journal-title":"ESC heart failure"},{"issue":"1","key":"10338_CR144","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2019-001012","volume":"6","author":"AL Beale","year":"2019","unstructured":"Beale AL, Warren JL, Roberts N, Meyer P, Townsend NP, Kaye D (2019) Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Open heart 6(1):e001012","journal-title":"Open heart"},{"key":"10338_CR145","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.757268","volume":"12","author":"AB Gevaert","year":"2021","unstructured":"Gevaert AB, Mueller S, Winzer EB, Duvinage A, Van de Heyning CM, Pieske-Kraigher E, Beckers PJ, Edelmann F, Wisl\u00f8ff U, Pieske B et al (2021) Iron deficiency impacts diastolic function, aerobic exercise capacity, and patient phenotyping in heart failure with preserved ejection fraction: a subanalysis of the OptimEx-Clin study. Front Physiol 12:757268","journal-title":"Front Physiol"},{"issue":"16","key":"10338_CR146","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/eurheartj\/ehad131","volume":"44","author":"FR Verelst","year":"2023","unstructured":"Verelst FR, Van Craenenbroeck EM, Gevaert AB (2023) Iron deficiency in heart failure across the spectrum of left ventricular ejection fraction: dotting the i\u2019s. Eur Heart J 44(16):1383\u20131385","journal-title":"Eur Heart J"},{"issue":"1","key":"10338_CR147","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ehf2.13753","volume":"9","author":"R L\u00f3pez-Vilella","year":"2022","unstructured":"L\u00f3pez-Vilella R, Lozano-Edo S, Arenas Mart\u00edn P, Jover-Pastor P, Ezzitouny M, Sorolla Romero J, Calvo Asensio M, Mart\u00ednez-Sol\u00e9 J, Guerrero Cervera B, S\u00e1nchez Mart\u00ednez JC et al (2022) Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction. ESC heart failure 9(1):133\u2013145","journal-title":"ESC heart failure"},{"key":"10338_CR148","unstructured":"Rull JLM (2019) Effects of iron therapy in heart failure with preserved ejection fraction and iron deficiency (PREFER-HF) - full text view - ClinicalTrials.gov [Internet]. [cited 2022 Oct 16]. Available from:\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03833336"},{"key":"10338_CR149","doi-asserted-by":"crossref","unstructured":"Doehner W (2020) Effect of IV iron in patients with heart failure with preserved ejection fraction - full text view - ClinicalTrials.gov [Internet]. [cited 2022 Oct 16]. Available from:\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03074591","DOI":"10.1016\/j.hfc.2019.12.002"},{"issue":"3","key":"10338_CR150","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.hfc.2021.02.008","volume":"17","author":"MN Kim","year":"2021","unstructured":"Kim MN, Park SM (2021) Current status of pharmacologic and nonpharmacologic therapy in heart failure with preserved ejection fraction. Heart Fail Clin 17(3):463\u2013482","journal-title":"Heart Fail Clin"},{"issue":"17","key":"10338_CR151","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/heartjnl-2021-319605","volume":"108","author":"AB Gevaert","year":"2022","unstructured":"Gevaert AB, Kataria R, Zannad F, Sauer AJ, Damman K, Sharma K, Shah SJ, Van Spall HGC (2022) Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart 108(17):1342\u20131350","journal-title":"Heart"},{"key":"10338_CR152","doi-asserted-by":"crossref","unstructured":"Zawadzka MM, Grabowski M, Kap\u0142on-Cie\u015blicka A (2022)\u00a0Phenotyping in heart failure with preserved ejection fraction: a key to find effective treatment. Adv Clin Exp Med : Offic organ Wroclaw Med University","DOI":"10.17219\/acem\/149728"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10338-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-023-10338-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10338-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T05:12:37Z","timestamp":1710479557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-023-10338-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":152,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["10338"],"URL":"https:\/\/doi.org\/10.1007\/s10741-023-10338-x","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"assertion":[{"value":"1 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}